Fireside Chat: Beyond the Needle: Oral, Intranasal & AI-Driven Drug Delivery Platforms - RANI THERAPEUTICS HOLDINGS INC

Explicit Guidance:

• Financial Runway: Updated cash guidance extends the runway to at least Q4 2027 (following a May $20 million raise), compared to the prior October guidance of "into 2028." This reflects a more conservative CFO approach using cash on hand rather than Chugai milestones in the baseline calculation.
• Chugai Milestones: Anticipates reporting on at least one early milestone tied to platform/manufacturing advancement in 2027; confident that Chugai will exercise options on future partnership targets.
• Clinical Data Timelines:
  • RT-114 (Obesity): Phase 1b repeat-dose study slated to start by end of 2026; Phase 1b data expected in 2027.
  • Stelara (Inflammatory Bowel Disease): No explicit date for the next data readout, but the company is "testing that this year" (referring to ISR data in an undisclosed study).

Business-Segment Outlook:

• Obesity/Metabolic (PG-102/RT-114): Targeting "competitive weight loss" with a "much more tolerable AE profile" compared to current oral semaglutide and oral tirzepatide; aims for weekly dosing with titration within one month (vs. four months for competitors).
• Obesity/Metabolic (PEG-Bio): Strategy to license diverse molecules (pentagonists, triagonists, siRNAs) via the PEG-Bio partnership to test and potentially reinvest in programs; not limited to obesity assets but will maintain a pipeline of diverse delivery programs.
• Platform Expansion: No limitations on modality (antibodies, proteins, peptides, oligos); anticipating interest from large pharma regarding monoclonal antibodies (mAbs) with Immunogenicity/Stopped-Resistance (ISR) issues where current delivery methods fail.
• Manufacturing: Cost of Goods Sold (COGS) projected to be "low single digits per pill" at scale due to simple materials (plastic, sugar, Alka-Seltzer) and no electronics; modeled as 12 pills/year for Stelara equivalent PK.

Market and Competitive Outlook:

• Oral Biologics Demand: Management asserts that despite current side effects, patients will "select an oral every time it's offered," validating the market shift.
• Competitive Differentiation: Positions RT-114 as the only proposed oral in development matching subcutaneous (sub-Q) dosing (weekly) with superior tolerability, whereas small-molecule orals (e.g., tirzepatide) require high API doses (100–300x) and frequent (daily/twice daily) administration.
• Pricing/Value: COGS of $100–$200 total per patient for weekly administration is deemed immaterial to final drug cost; bioavailability >100% allows for potential higher serum concentrations at lower doses.

Macro / Industry Outlook:

• Regulatory/Investor Sentiment: Management notes a historical barrier where the technology sounded like "science fiction" to investors, but this has shifted following a $1.1 billion Chugai deal and significant institutional/sovereign fund investment.
• Capital Markets: Successfully executed a concurrent financing with the Chugai deal and a $60 million registered direct offering in October (2025) and a $20 million raise in May (2026).

Strategic Initiatives:

• Partnerships:
  • Chugai: 50-50 cost share and revenue split; markets split (Chugai: Asia; Rani: US, Europe, UK, Australia, Canada); Chugai to exercise options on up to five additional targets.
  • PEG-Bio: Collaboration to test obesity/metabolic molecules (GLP-1, siRNAs) to generate data for partner or internal investment.
  • Shugai (Chugai): Initial $10M up-front; deal expanded to include more targets following two years of diligence.
• Capacity/Operations: Moving toward mass manufacturing with de minimis input costs; utilizing existing clinical efficiency (known drugs, single-dose studies) to lower burn rates, with partners bearing 50–100% of study costs.

Risks and Headwinds to Outlook:

• Clinical Validation: Skeptics question if >150% bioavailability and low variability will hold in larger, repeat-dose studies; management dismisses the exact percentage as less critical than achieving bioequivalence or superiority to sub-Q.
• Historical Hurdles: Prior early programs discontinued due to investor skepticism regarding the complexity of the device, though management frames this as a "perception" hurdle now cleared by the Chugai deal.
• Regulatory/Execution Risk: No explicit guidance provided for ISR (Immunogenicity/Stopped-Resistance) data until it is confirmed; management declines to guide on ISR data timing pending results.
• Dilution Risk: While current runway is secured through 2027, future funding may require repeated dilution if Chugai milestones are delayed, though management cites "stream of upfronts and milestones" as a hedge.

Management Tone on the Future:

• Confidence: High confidence in the platform's scalability and commercial viability ("best drug ever," "holy grail" of drug delivery).
• Conservatism: CFO adopted a "more conservative" stance on cash guidance compared to previous periods to ensure runway stability, excluding future Chugai milestones from the baseline.
• Differentiation: Strong belief that the oral injectable mechanism (weekly dosing, no sharp pain, dissolving needle) will drive patient adherence despite the current dominance of daily oral small molecules.

Miscellaneous:

• Stock Ticker: RANI (Ronnie Therapeutics).
• Clinical Progress: Completed four clinical studies (250+ oral pills administered) showing equivalent bioavailability to sub-Q for various modalities.